Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-05-31
2011-05-31
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S181100, C424S183100, C530S387100, C530S387300, C530S391100
Reexamination Certificate
active
07951369
ABSTRACT:
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5677427 (1997-10-01), Goldenberg et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6759045 (2004-07-01), Goldenberg et al.
patent: 6962702 (2005-11-01), Hansen et al.
Ezzell. Cancer “vaccines”: an idea whose time has come? Journal of NIH Research, 1995. vol. 7 pp. 46-49.
Forni, Lollini, Musiani, and Colombo. Immunoprevention of Cancer: Is the time ripe? Cancer Research, 2000. vol. 60, pp. 2571-2575.
Donnelly. Cancer vaccine targets leukemia. Nature Medicine, 2003. vol. 9, pp. 1354-1356.
De Gruijl and Curiel. Cancer vaccine strategies get bigger and better. Nature Medicine, 1999. vol. 5, pp. 1124-1125.
Chatterjee, Foon, and Kohler. Idiotypic antibody immunotherapy of cancer. Cancer Immunology Immunotherapy, 1994. vol. 38, pp. 75-82.
Bodey, Bodey, Siegel, and Kaiser. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Research, 2000. vol. 20, pp. 2665-2676.
Lee, Wang, Nielsen, Wunderlich, Migueles, Connors, Steinberg, Rosenberg, and Marincola. Increased vaccine specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. Journal of Immunology, 1999. vol. 163, pp. 6292-6300.
Becker et al. “Detection of Soft-Tissue Infections and Osteomyelitis Using a Technetium-99m-Labeled Anti-Granulocyte Monoclonal Antibody Fragment” J. of Nucl. Med. (1994) 35(9):1436-1443.
Cruse et al. Illustrated Dictionary of Immunology, 1995. CRC Press, Boca Raton FL, p. 65.
Decristoforo et al. “Failure of Labelling of Anti-Granulocyte Antibody” Eur. J. Nucl. Med. (1993) 20(6):565-566.
Hansen et al. “Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen” Cancer (1993) 71:3478-3485.
Orlandi et al. “Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction” Proc. of the Natl. Acad. Sci. USA, (1989) 86:3833-3837.
Sato et al. “Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods for Selecting Human Framework Regions” Mol. Immunol. (1994) 31(5):371-381.
Ward et al. “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted fromEscherichia Coli” Nature (1989) 341:544-546.
Goldenberg David M.
Hansen Hans J.
Gussow Anne M.
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Chimeric, human and humanized anti-granulocyte antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric, human and humanized anti-granulocyte antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric, human and humanized anti-granulocyte antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641711